Protein aggregation and immunogenicity of biotherapeutics
NB Pham, WS Meng - International journal of pharmaceutics, 2020 - Elsevier
Recombinant proteins are the mainstay of biopharmaceuticals. A key challenge in the
manufacturing and formulation of protein biologic products is the tendency for the active …
manufacturing and formulation of protein biologic products is the tendency for the active …
T cell recognition of tumor neoantigens and insights into T cell immunotherapy
MJW Sim, PD Sun - Frontiers in Immunology, 2022 - frontiersin.org
In cancer, non-synonymous DNA base changes alter protein sequence and produce
neoantigens that are detected by the immune system. For immune detection, neoantigens …
neoantigens that are detected by the immune system. For immune detection, neoantigens …
Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA
Public neoantigens (NeoAgs) represent an elite class of shared cancer-specific epitopes
derived from recurrently mutated driver genes. Here we describe a high-throughput platform …
derived from recurrently mutated driver genes. Here we describe a high-throughput platform …
Prediction of neo-epitope immunogenicity reveals TCR recognition determinants and provides insight into immunoediting
J Schmidt, AR Smith, M Magnin, J Racle, JR Devlin… - Cell Reports …, 2021 - cell.com
CD8+ T cell recognition of peptide epitopes plays a central role in immune responses
against pathogens and tumors. However, the rules that govern which peptides are truly …
against pathogens and tumors. However, the rules that govern which peptides are truly …
Structural and physical features that distinguish tumor-controlling from inactive cancer neoepitopes
JM Custodio, CM Ayres, TJ Rosales… - Proceedings of the …, 2023 - National Acad Sciences
Neoepitopes arising from amino acid substitutions due to single nucleotide polymorphisms
are targets of T cell immune responses to cancer and are of significant interest in the …
are targets of T cell immune responses to cancer and are of significant interest in the …
[HTML][HTML] Intracellular trafficking of HLA-E and its regulation
W He, E Gea-Mallorquí, H Colin-York… - The Journal of …, 2023 - ncbi.nlm.nih.gov
Interest in MHC-E–restricted CD8+ T cell responses has been aroused by the discovery of
their efficacy in controlling simian immunodeficiency virus (SIV) infection in a vaccine model …
their efficacy in controlling simian immunodeficiency virus (SIV) infection in a vaccine model …
HLA class I signal peptide polymorphism determines the level of CD94/NKG2–HLA-E-mediated regulation of effector cell responses
Z Lin, AA Bashirova, M Viard, L Garner, M Quastel… - Nature …, 2023 - nature.com
Human leukocyte antigen (HLA)-E binds epitopes derived from HLA-A, HLA-B, HLA-C and
HLA-G signal peptides (SPs) and serves as a ligand for CD94/NKG2A and CD94/NKG2C …
HLA-G signal peptides (SPs) and serves as a ligand for CD94/NKG2A and CD94/NKG2C …
High-throughput characterization of HLA-E-presented CD94/NKG2x ligands reveals peptides which modulate NK cell activation
BD Huisman, N Guan, T Rückert, L Garner… - Nature …, 2023 - nature.com
HLA-E is a non-classical class I MHC protein involved in innate and adaptive immune
recognition. While recent studies have shown HLA-E can present diverse peptides to NK …
recognition. While recent studies have shown HLA-E can present diverse peptides to NK …
High-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12D
Complete cancer regression occurs in a subset of patients following adoptive T cell therapy
(ACT) of ex vivo expanded tumor-infiltrating lymphocytes (TILs). However, the low success …
(ACT) of ex vivo expanded tumor-infiltrating lymphocytes (TILs). However, the low success …
Structural dissimilarity from self drives neoepitope escape from immune tolerance
JR Devlin, JA Alonso, CM Ayres, GLJ Keller… - Nature chemical …, 2020 - nature.com
T-cell recognition of peptides incorporating nonsynonymous mutations, or neoepitopes, is a
cornerstone of tumor immunity and forms the basis of new immunotherapy approaches …
cornerstone of tumor immunity and forms the basis of new immunotherapy approaches …